Continuous use at a maintenance dose is likely the more effective strategy for most people
doi: 10.3389/fonc.2023.1231460 Received 30 May 2023 Accepted 08 August 2023 Published 22 August 2023 Volume 13 - 2023 Edited by Jian-Jun Wei, Northwestern University, United States Reviewed by Zhi-Bin Wang, Xiangya School of Medicine, Central South University, China
This triple-agonist approach targets GLP-1, GIP, and glucagon receptors, creating a synergistic effect that produces weight loss results exceeding anything previously achieved in clinical trials
It also boosts your energy, helps with pain, and improves sleep
Although permanent discontinuation of therapy was recorded in 5.5% of patients, the reasons varied and included elective switches to other incretin-based agents, perceived inadequate efficacy, and patient request
Here are the main ways they support weight loss: You feel less hungry and have fewer food cravings You feel full after eating smaller amounts of food Your blood sugar is better controlled, which can improve overall health For many people, this makes it easier to follow a healthier eating plan and lose weight in a steady, long-term way